Navigation Links
Implications of Statin Therapy in Bladder Cancer Patients

Smoking is one of the major risk factors for the development of bladder cancer and is also associated with cardiac disease, hyperlipidemia, and atherosclerosis.//

Consequently, it is not uncommon for patients with bladder cancer to have concomitant cardiac disease and hyperlipidemia. The 3-Hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors (statins) are widely used in the treatment of hyperlipidemia and, in fact are available as over the counter drugs in some countries due to a perceived significant impact on overall mortality from cardiac disease.

In the January issue of the New England Journal of Medicine, Hoffmann and colleagues reported on a series of patients with bladder cancer who were treated with BCG. Of the 84 patients, 19 were also receiving statin therapy. After a median follow-up of 46 months, it appeared that patients receiving statin therapy had a higher incidence of disease progression (10 of 19 (53%) versus 12 of 65 (18%), p = 0.004). The number of recurrences did not differ significantly between the groups. While a larger number of patients on statin therapy underwent radical cystectomy, among the patients who underwent radical cystectomy, the number in whom metastases developed and the time to their development were similar in the two groups. The authors concluded that 'Our observations suggest that the discontinuation of statin therapy during BCG immunotherapy might improve the clinical outcome'.

In the March issue of NEJM, Kamat and Wu reported on the outcomes of a cohort of 156 patients who received BCG treatment; 39 took statins during BCG, and 117 did not. After a median follow-up: 56 months, there was no difference in recurrences (59% in both groups, p = 0.801), tumor progression (30% vs. 28%, p = 0.57) or deaths. Furthermore, there was no difference in outcomes, even when accounting for whether patients received only induction BCG therapy or induction BCG plus maintenance therapy.

At the current time, treating urologists and patients should view the available data as inconclusive, at best. This is especially important since patients with bladder cancer commonly use statins, and some reports have documented antiproliferative effects of statins urothelial cancer cell lines. Further more, since it has been shown that discontinuation of statin therapy can have adverse cadiac outcomes, it seems prudent to continue statin therapy in bladder cancer patients who are on BCG, until more robust data to suggest otherwise are presented.

Source-Newswise
'"/>




Related medicine news :

1. Genetic Eye Disorder Can Have Other Implications
2. New Way to Open Cellular Ion Channels, Implications for Drug Design
3. Statins reduce heart attacks
4. Statins reduce risks for angioplasty patients
5. Statins Found To Be Helpful For Patients With Arthritis
6. Long-Term Benefits Of Statins Questioned
7. Higher Statin Dose Safely Reduces Stroke and Cardiac Arrest
8. Use of Statin can help in recovery from stroke
9. Statins Not Effective In Treating Calcific Aortic Stenosis
10. Statins Gives New Hope for Increased Survival Rate of Heart Failure Patients
11. The Effects of Statins Questioned
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/24/2016)... Marne, Michigan (PRWEB) , ... June 24, 2016 , ... ... awareness about the dangers associated with chronic pain and the benefits of holistic treatments, ... for individuals who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced ... attorneys chosen by their peers for this recognition are considered among the top 2 ... received special honors as members of this year’s Legal Elite Hall of Fame: ...
(Date:6/24/2016)... ... ... makers of Topricin and MyPainAway Pain Relief Products, join The ‘Business for a Fair Minimum ... by 2020 and then adjusting it yearly to increase at the same rate as the ... wage floor does not erode again, and make future increases more predictable. , The company ...
(Date:6/24/2016)... NY (PRWEB) , ... June 24, 2016 , ... ... Haute Living, is proud to recognize Dr. Barry M. Weintraub as a prominent ... “the most beautiful women in the world, and the most handsome men, look ...
(Date:6/24/2016)... ... 24, 2016 , ... National recruitment firm Slone Partners is pleased ... and genomics experience, as Vice President of North American Capital Sales at HTG ... leading the sales team in the commercialization of the HTG EdgeSeq system and associated ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... Analysis 2016 - Forecast to 2022" report to their ... contains up to date financial data derived from varied research ... trends with potential impact on the market during the next ... which comprises of sub markets, regional and country level analysis. ...
(Date:6/23/2016)... , June 23, 2016 , ... on Thursday, July 7, 2016 , , , , LOCATION: ... , , , , EXPERT PANELISTS:  , , , ... Senior Industry Analyst, Christi Bird; Senior Industry Analyst, Divyaa Ravishankar and ... The global pharmaceutical industry is witnessing an exceptional era. ...
Breaking Medicine Technology: